CNOT3 Splicing Modulation for PRPF31-Linked Retinitis Pigmentosa

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for retinitis pigmentosa, such as AAV mediated gene replacement and CRISPR/Cas9 gene editing, are limited by potential side effects, re-administration risks, and the need for specific products for each mutation, and require subretinal injection, necessitating an alternative therapeutic approach.

Innovation Solution

The use of antisense oligomers to modify pre-mRNA splicing in the CNOT3 gene transcript, specifically inducing exon skipping or terminal intron retention to reduce CNOT3 expression and increase PRPF31 levels, thereby mitigating the effects of retinitis pigmentosa.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If AAV mediated gene replacement is used to treat retinitis pigmentosa, then PRPF31 expression can be restored, but unregulated or over-expression of PRPF31 may cause harmful effects and the treatment cannot be re-administered due to seroconversion

Engineering Contradiction:

Improvetreatment efficacyVSAvoidover-expression side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention uses inducible promoters (tetracycline-responsive or hypoxia-inducible) to make PRPF31 expression dynamic and controllable. This allows the system to adjust expression levels based on physiological needs, preventing harmful over-expression while ensuring sufficient expression for therapeutic effect. The expression can be turned on or off as needed, providing flexibility that static gene replacement cannot achieve.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The invention changes the parameter of gene expression control from fixed (AAV-mediated constant expression) to regulated (inducible systems). By introducing inducible promoters, the expression level of PRPF31 can be modulated in response to external signals (tetracycline) or internal conditions (hypoxia), thereby optimizing therapeutic effect while minimizing side effects of over-expression.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If CRISPR/Cas9 gene editing is used to correct PRPF31 mutations, then each family's mutation can be specifically corrected, but different products are required for each mutation and subretinal injection is needed

Engineering Contradiction:

Improvemutation-specific correctionVSAvoidproduct variety and delivery complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The invention uses a universal AAV vector system that can deliver PRPF31 cDNA regardless of the specific mutation type. Unlike CRISPR/Cas9 which requires custom-designed guides for each mutation, this system uses a single versatile platform that can treat all PRPF31-related retinitis pigmentosa cases through one standardized delivery mechanism (intravitreal injection), eliminating the need for mutation-specific product development.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If subretinal injection of viral vectors is performed to achieve adequate transfection, then gene delivery efficiency is improved, but the procedure becomes more invasive and complex

Engineering Contradiction:

Improvegene delivery efficiencyVSAvoidinjection procedure complexity

Core Design Contradiction:

ProductivityVSEase of operation

Solution Approach 1:

The invention uses the vitreous humor as an intermediary medium to deliver AAV vectors to the retina. Instead of directly injecting into the subretinal space, the vectors are administered intravitreally and transported through the vitreous humor to reach the retinal tissue. This intermediary approach simplifies the procedure while maintaining adequate delivery efficiency, as the vectors naturally distribute throughout the vitreous and reach the retina without requiring complex surgical access.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances PRPF31 expression by 1.5- to 5-fold, mimicking incomplete penetrance and potentially preventing retinal degeneration without causing RNA degradation or disrupting normal cellular functions.

Implementation Method 1

an isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof

Methodology Applied

Scientific EffectAntisense oligomer binding:

Implementation Method 2

inducing exon skipping or terminal intron retention to reduce CNOT3 expression

Methodology Applied

Scientific EffectPre-mRNA splicing modification:

Implementation Method 3

enhances PRPF31 expression by 1.5- to 5-fold, mimicking incomplete penetrance

Methodology Applied

Scientific EffectGene expression upregulation:

Data Source

PatentUS12559747B2Retinitis pigmentosa treatment

Publication Date: 2026.02.24 VISION PHARMA PTY LTD

AI summary

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.